Andrew Armstrong
MD, MSc
Professor of Medicine, Surgery, Pharmacology and Cancer Biology
👥Biography 个人简介
Andrew Armstrong is a prostate cancer clinician-scientist at Duke University who contributed to the SPARTAN trial and has led investigations into biomarkers predicting response to AR-targeted therapies in nmCRPC. His translational research program examines AR splice variants including AR-V7 as mechanisms of resistance to enzalutamide and apalutamide. He has developed and validated quality-of-life instruments and patient-reported outcome measures for nmCRPC clinical trials. Armstrong leads a multidisciplinary prostate cancer program integrating clinical care with genomic and biomarker research.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Andrew Armstrong 的研究动态
Follow Andrew Armstrong's research updates
留下邮箱，当我们发布与 Andrew Armstrong（Duke Cancer Institute）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment